1290 Rancho Conejo Blvd
6 articles with Capsida Biotherapeutics
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver
Capsida Biotherapeutics, Inc.,today announced research published in Nature Neuroscience that demonstrated the ability to engineer and select novel capsid variants, with improved enrichment in the brain and decreased liver targeting following intravenous (IV) administration in rodents and non-human primates.
Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO
Capsida Biotherapeutics Inc. today announced the appointment of Peter Anastasiou as the company's Chief Executive Officer (CEO) and the promotions of Capsida co-founders Nicholas Flytzanis, Ph.D., to Chief Scientific Officer (CSO) and Nick Goeden, Ph.D., to Chief Technology Officer (CTO).
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of its state-of-the-art manufacturing facility in Thousand Oaks.
The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.